- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management
Robert M. Rifkin, MD, FACP, discusses how the MagnetisMM-3 update at the 66th American Society of Hematology Annual Meeting and Exposition sheds light on elranatamab’s role in relapsed/refractory multiple myeloma while panelists discuss how emerging data on bispecific antibodies and combination strategies could shape treatment timing and improve outcomes, especially in heavily pretreated patients.
EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies
EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management
EP: 3.Proactive CRS Management: The Role of Tocilizumab and Beyond
EP: 4.Expanding Bispecific Therapies to Community Settings: Challenges and Innovations
EP: 5.Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
EP: 6.Streamlining Transitions Between Academic and Community Centers
EP: 7.Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery
Video content above is prompted by the following:
- The MagnetisMM-3 update at the 66th American Society of Hematology Annual Meeting and Exposition provided critical insights into elranatamab for patients with relapsed/refractory multiple myeloma. What are your key takeaways from this update, and how do these data influence the role of elranatamab in the current treatment paradigm?
- With growing data on bispecifics, what are your perspectives on the ideal timing for integrating these therapies into treatment plans, especially in heavily pretreated patients vs earlier lines?
- There is increasing interest in combining bispecific antibodies with other therapies. Which combination strategies do you find most promising, and what potential do they hold for enhancing outcomes in relapsed/refractory multiple myeloma?
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
